Logo image of GSD.CA

DEVONIAN HEALTH GROUP INC (GSD.CA) Stock Fundamental Analysis

TSX-V:GSD - TSX Venture Exchange - CA2518348008 - Common Stock - Currency: CAD

0.185  0 (0%)

Fundamental Rating

3

GSD gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 35 industry peers in the Pharmaceuticals industry. The financial health of GSD is average, but there are quite some concerns on its profitability. GSD is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

2

1. Profitability

1.1 Basic Checks

GSD had negative earnings in the past year.
In the past year GSD had a positive cash flow from operations.
In the past 5 years GSD always reported negative net income.
In the past 5 years GSD reported 4 times negative operating cash flow.
GSD.CA Yearly Net Income VS EBIT VS OCF VS FCFGSD.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 2M -2M 4M -4M

1.2 Ratios

GSD has a Return On Assets of -2.59%. This is in the better half of the industry: GSD outperforms 70.27% of its industry peers.
GSD has a better Return On Equity (-5.96%) than 67.57% of its industry peers.
Industry RankSector Rank
ROA -2.59%
ROE -5.96%
ROIC N/A
ROA(3y)-14.65%
ROA(5y)-18.61%
ROE(3y)-20.65%
ROE(5y)-30.61%
ROIC(3y)N/A
ROIC(5y)N/A
GSD.CA Yearly ROA, ROE, ROICGSD.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10 -20 -30 -40 -50

1.3 Margins

Looking at the Gross Margin, with a value of 32.06%, GSD is in line with its industry, outperforming 54.05% of the companies in the same industry.
GSD's Gross Margin has declined in the last couple of years.
GSD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 32.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-8.51%
GSD.CA Yearly Profit, Operating, Gross MarginsGSD.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100 -150 -200

More info and screens

5

2. Health

2.1 Basic Checks

GSD does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for GSD has been increased compared to 1 year ago.
Compared to 5 years ago, GSD has more shares outstanding
Compared to 1 year ago, GSD has an improved debt to assets ratio.
GSD.CA Yearly Shares OutstandingGSD.CA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M
GSD.CA Yearly Total Debt VS Total AssetsGSD.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

GSD has an Altman-Z score of 0.58. This is a bad value and indicates that GSD is not financially healthy and even has some risk of bankruptcy.
GSD has a Altman-Z score of 0.58. This is in the better half of the industry: GSD outperforms 70.27% of its industry peers.
The Debt to FCF ratio of GSD is 0.26, which is an excellent value as it means it would take GSD, only 0.26 years of fcf income to pay off all of its debts.
The Debt to FCF ratio of GSD (0.26) is better than 94.59% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that GSD is not too dependend on debt financing.
With an excellent Debt to Equity ratio value of 0.01, GSD belongs to the best of the industry, outperforming 86.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.26
Altman-Z 0.58
ROIC/WACCN/A
WACC8.54%
GSD.CA Yearly LT Debt VS Equity VS FCFGSD.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5M 10M 15M

2.3 Liquidity

GSD has a Current Ratio of 1.13. This is a normal value and indicates that GSD is financially healthy and should not expect problems in meeting its short term obligations.
GSD has a worse Current ratio (1.13) than 70.27% of its industry peers.
GSD has a Quick Ratio of 1.13. This is a normal value and indicates that GSD is financially healthy and should not expect problems in meeting its short term obligations.
GSD has a Quick ratio (1.13) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 1.13
Quick Ratio 1.13
GSD.CA Yearly Current Assets VS Current LiabilitesGSD.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M

More info and screens

4

3. Growth

3.1 Past

GSD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 80.07%, which is quite impressive.
Looking at the last year, GSD shows a very strong growth in Revenue. The Revenue has grown by 598.15%.
The Revenue has been growing by 24.58% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)80.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.02%
Revenue 1Y (TTM)598.15%
Revenue growth 3Y129.46%
Revenue growth 5Y24.58%
Sales Q2Q%359.8%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
GSD.CA Yearly Revenue VS EstimatesGSD.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
GSD.CA Yearly EPS VS EstimatesGSD.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GSD. In the last year negative earnings were reported.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GSD.CA Price Earnings VS Forward Price EarningsGSD.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

62.16% of the companies in the same industry are more expensive than GSD, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, GSD is valued cheaply inside the industry as 94.59% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 3.1
EV/EBITDA 222.7
GSD.CA Per share dataGSD.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.05 0.1 0.15

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

GSD does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DEVONIAN HEALTH GROUP INC

TSX-V:GSD (3/7/2025, 7:00:00 PM)

0.185

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-20 2024-12-20
Earnings (Next)03-25 2025-03-25
Inst OwnersN/A
Inst Owner ChangeN/A
Ins Owners14.2%
Ins Owner ChangeN/A
Market Cap27.42M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.22
P/FCF 3.1
P/OCF 3.09
P/B 1.89
P/tB 5.8
EV/EBITDA 222.7
EPS(TTM)-0.01
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)0.06
FCFY32.24%
OCF(TTM)0.06
OCFY32.32%
SpS0.15
BVpS0.1
TBVpS0.03
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -2.59%
ROE -5.96%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 32.06%
FCFM 39.48%
ROA(3y)-14.65%
ROA(5y)-18.61%
ROE(3y)-20.65%
ROE(5y)-30.61%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-8.51%
F-Score5
Asset Turnover0.67
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF 0.26
Debt/EBITDA 1.47
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion 11450.4%
Profit Quality N/A
Current Ratio 1.13
Quick Ratio 1.13
Altman-Z 0.58
F-Score5
WACC8.54%
ROIC/WACCN/A
Cap/Depr(3y)3.28%
Cap/Depr(5y)2.81%
Cap/Sales(3y)1.16%
Cap/Sales(5y)1.16%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)80.07%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%51.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)598.15%
Revenue growth 3Y129.46%
Revenue growth 5Y24.58%
Sales Q2Q%359.8%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y85.05%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y339.76%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y345.63%
OCF growth 3YN/A
OCF growth 5YN/A